Primary aldosteronism (PA) is previous thought as a rare disease. However, due to the improvement of diagnostic tool, the prevalance increases to 5-13% in hypertensive patients. Compared to essential hypertensive patients, PA patients have higher prevalence of cardiovascular disease and arrhythmia. Nearly half of PA patients are aldosterone-producing adenoma (APA) subtype, and can be cured by surgery. After appropriate treatment (including surgery and medical treatment), the blood pressure can be controlled well and the risk cardiovascular disease can also be much decreased.

Due to the importance of PA, our research team (Taiwan Primary Aldosteronism Study Group, TAIPAI Study Group) was assembled in 2006 to do the multi-discipline research on this important issue. There are more than 700 cases in our data registry which is the number 1 in Asia (update in 2014 Dec). About 50 PA patient is new-diagnosed or referred to our team each year. We have established the standard operation procedure of PA diagnosis in 2011. Currently, there are ten hospitals (more than 30 doctors and researchers) in TAIPAI study group. Until 2014 Dec, more than 25 papers published from TAIPAI study group. TAIPAI study group is one of the most suitable team to do PA research. Our group also closely cooperate with other PA study group and society. Under the support of Asia-Pacific Congress of Hypertension (APCH) and Taiwan Hypertension Society, we give a satellite symposium focus on PA at 8^th APCH congress in 2011. In this year (2015), we (and Prof. Stowasser in Australia) will give another PA satellite symposium at 11^th APCH congress in Bali.

We are pleased to have any opportunity for cooperation with other PA study group. Please contact to us.